Aflac Inc Earnings - Q3 2026 Analysis & Highlights
Byline: Aflac reported solid third-quarter 2026 results, with growth in U.S. sales and premiums, Japan sales recovering after a cyber-related disruption, favorable actuarial assumption updates, active portfolio repositioning, and continued capital returns.
Key financial results
Net earnings were $0.61 per diluted share; adjusted earnings were $2.43 per diluted share in the CEO’s overview, while the CFO reported adjusted EPS of $2.46 excluding foreign currency effects, down 1.2% year over year.
The Q3 actuarial assumption update increased EPS by $0.71; total pre-tax reserve remeasurement gains, including deferred profit liability, were $447 million.
Results included $40 million, or $0.06 per diluted share, of Japan cybersecurity expenses and enhancements; variable investment income was $22 million, or $0.03 per diluted share, below long-term return expectations.
Adjusted ROE was 17.8%, or 23.7% excluding foreign currency remeasurement; adjusted book value per share declined 6.4% excluding foreign currency remeasurement.
The CFO characterized the quarter’s results as solid.
Business segment results
Aflac Japan: Sales fell 4% to ¥18.8 billion against a difficult prior-year comparison, but were up 3% for the first nine months; earned premiums in yen declined 2%, while underlying earned premiums declined 1.2%.
Japan’s premium persistency was 92.9%; its benefit ratio was 49.2%, and its pre-tax margin was 44.4%, with year-over-year comparisons affected by a larger actuarial assumption unlock in the prior year.
Japan’s expense ratio was 21.2%, including an estimated 180-basis-point increase from cybersecurity costs and enhancements; adjusted net investment income in yen rose 3.7%.
Aflac U.S.: Sales increased 3.5% year over year, net earned premiums grew 3.3%, and persistency was 79.7%.
The U.S. benefit ratio was 40.7%, its expense ratio was 37%, and its pre-tax margin was 27.7%; the reported benefit and margin improvements were primarily influenced by the actuarial assumption unlock.
U.S. adjusted net investment income declined 0.9% for the quarter.
U.S. group business grew 17% in earned premiums; group life, absence and disability grew 29%, dental and vision 55%, and voluntary benefits 7.5%, while the individual platform declined about 1.5%.
Corporate and other: Adjusted revenues rose 5% to $360 million and pre-tax adjusted earnings were $72 million, versus $69 million a year earlier; earnings included $91 million of remeasurement gains related to assumption unlocking and new reinsurance transactions.
Capital allocation
Aflac returned $1.1 billion to shareholders in Q3 and $3.7 billion in the first nine months through dividends and share repurchases.
In Q3, the company repurchased $804 million of stock and paid $305 million in dividends.
Aflac marked 44 consecutive years of dividend increases in 2026.
Adjusted leverage was 22.6%, within the company’s 20%–25% target range; unencumbered liquidity was $2.7 billion, or $1.7 billion above its minimum balance.
The company estimated regulatory ESR at 225%, or 238% including the undertaking-specific parameter, and combined RBC slightly above 575%.
A Japan reinsurance transaction ceded approximately ¥500 billion of cancer-policy reserves and was estimated to release about $1 billion of capital over time for potential redeployment.
Aflac Japan had ceded roughly 15% of its total FSA reserves to Aflac Bermuda after the transaction, compared with 10% before it; the internal risk limit is 30%.
Industry trends and dynamics
Management said rising healthcare costs in Japan and the U.S. are putting pressure on household budgets and increasing the need for supplemental insurance against unexpected medical expenses.
Aflac reported favorable cancer-related hospitalization and mortality experience in Japan, while persistency remained solid; lapse and reissue activity on recently launched products was somewhat elevated but declined during the quarter.
Aflac said its U.S. group life and disability business was growing, and management described behavioral-health-related disability pressure at peers; Aflac characterized its own relevant business as small and said its loss ratio was down a few basis points year over year.
Japan’s first-sector savings business is more capital-intensive and exposed to macroeconomic factors, particularly interest rates, whereas management described third-sector business as less affected by external macro factors and easier to manage for risk.
Competitive landscape
Aflac identified its diverse distribution network—including agencies, alliance partners and banks—as a competitive advantage for reaching consumers across demographics and life stages.
Management cited the company’s seven decades of experience, its pioneering role in cancer insurance, and its recognized brand as differentiators supporting customer financial protection.
In the U.S., Aflac said dental and vision products are being sold alongside voluntary benefits; for every $1 of dental product sold, approximately $0.90 to $1 of voluntary-benefit product was also sold.
Aflac said its disciplined underwriting, strong renewal execution and ability to obtain rate action supported continued growth in group disability despite reported peer pressure.
Macroeconomic environment
Higher yen interest rates supported demand and attractive new-business returns for Tsumitasu, while Aflac said first-sector savings remains sensitive to interest rates and requires flexibility in pricing and growth.
Aflac said weakening of the yen increased income on U.S.-dollar-denominated assets in Japan, while yen-dollar exchange-rate movements affect its leverage ratio because approximately 64% of debt is denominated in yen.
Higher rates also enabled the company to reposition lower-yielding Japanese government bonds, although management noted that higher rates can increase unrealized losses on legacy assets.
The company said its investment teams were increasing loan reserves in response to continued commercial real estate valuation pressure and longer-run expectations for middle-market loan performance.
Growth opportunities and strategies
Aflac said its preferred new-business capital opportunities remain writing policies in its U.S. and Japan operations, where management sees the best returns.
Management described external reinsurance as a potential longer-term opportunity, citing Aflac’s balance-sheet capabilities and diversification from writing life and annuity business originating in Japan; it expects relatively limited capital consumption.
Aflac Japan said Tsumitasu represented approximately 20% of total sales and helped expand its customer base, including younger and middle-aged customers, while supporting concurrent sales of cancer and medical insurance.
Management said Japan’s total first-sector savings in force was still shrinking because the Ways block was running off faster than Tsumitasu was being added, while stating it was comfortable continuing to grow the business under current conditions.
Aflac repositioned $2.3 billion of Japanese government bonds in Q3; management said the quarter’s activity improved future net investment income by more than $30 million, while year-to-date portfolio actions added more than $80 million of annual net investment income.
Aflac said it would continue to evaluate Bermuda reinsurance transactions, with timing and size determined by Aflac Japan’s needs rather than following a fixed, linear schedule.
Japan’s customer-support response to a cyber incident temporarily suspended certain initiatives, including direct mail and outbound calls; those activities resumed in September, and sales had returned to normal by the fourth quarter.
Financial Guidance and Outlook
Aflac expects 2026 Japan sales to exceed 2025; management said October sales were as expected and fourth-quarter sales had returned to normal.
For 2026, Aflac Japan expects its benefit ratio to be slightly below the 60%–63% range, its expense ratio toward the lower end of the 20%–23% range, and its pre-tax margin in a raised range of 35%–38%.
For 2026, the U.S. benefit ratio is expected to be below the 48%–52% range, the expense ratio in the middle of the 36%–39% range, and the pre-tax margin above the 17%–20% range.
The assumption update is expected to lower future benefit ratios by approximately 70 basis points in Japan, 60 basis points in the U.S., and 320 basis points in Aflac Re Bermuda, all else equal.
Aflac U.S. management expected sales momentum to continue in Q4 and said the quarter would include an extra week of productivity; it expected performance to be better than the prior year.
Management said future switch trades would depend on market conditions and multiple considerations, including accounting, taxes, liquidity, capital and unrealized losses, and cautioned that achieving the same level of impact as prior trades could be difficult.
Aflac said it would remain flexible and tactical in deploying capital, while continuing dividends and share repurchases and pursuing risk-adjusted returns with a meaningful spread over its cost of capital.
